Mentored Patient Oriented Research in Lymphoma

以患者为导向的淋巴瘤研究指导

• 批准号: 10071361
• 负责人: CHRISTOPHER R FLOWERS
• 金额: $ 14.78万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10071361
• 关键词: Mentored; Patient; Oriented; Research; Lymphoma

PROJECT SUMMARY Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma in the US, affects ~22,000 people/year and is a significant clinical problem for cancer patient-oriented research in that it is a curable disease, but one with heterogeneous outcomes. Despite >58% of patients being alive and cured at 5 years with modern chemo- immunotherapy, outcomes are significantly worse for patients who are African American (AA), uninsured, or those who have activated B-cell-like (ABC) biological subtype or a high international prognostic index score. Dr. Flowers has described patient outcomes for biological subtypes of DLBCL, identified racial and socioeconomic disparities in DLBCL, and modeled how race/ethnicity, biological, and socioeconomic factors interact to influence DLBCL survival. However, at present there is no unifying, comprehensive prognostic system that incorporates these parameters. To address the current and long-term unmet health needs of the lymphoma patient population, Drs. Flowers and Cerhan established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (U01CA195568), which will support a broad research agenda aimed at identifying novel clinical, epidemiologic, host genetic, tumor, and treatment factors that significantly influence prognosis and survivorship. LEO will: 1) Recruit >12,000 newly diagnosed lymphoma patients (including 1,000 AA and 1,400 Hispanic participants and 3,700 DLBCLs); 2) Build a tissue bank with extracted tumor DNA and RNA, peripheral blood DNA, serum and plasma; 3) Annotate all cases with clinical, epidemiologic, pathology, and treatment data; 4) Prospectively follow patients to ascertain disease progression/relapse, retreatment, second cancers, survival, and patient-reported outcomes; and 5) Facilitate research projects that use this infrastructure. In addition, Dr. Flowers will utilize LEO protocols and the Georgia state SEER registry to construct a population-based cancer disparities cohort study that will: 1) examine the relationships between DLBCL genomics, ABC subtype, race, pattern of presentation, treatment and survival; 2) develop a computer micro-simulation model that incorporates these data into an online prognostic tool for DLBCL as a decision support tool for patients, clinicians, and other investigators. Dr. Flowers will build on his national leadership on the American Society Hematology Committee on Promoting Diversity, American Society Clinical Oncology Health Disparities Committee, and in clinical research mentorship programs for ASH and the Lymphoma Research Foundation and utilize these resources to recruit, train, and develop a cadre of junior faculty, hematology/oncology fellows, housestaff, and medical students in cancer patient-oriented research with a particular focus on developing minority investigators who will lead the field.

项目概要 弥漫性大 B 细胞淋巴瘤 (DLBCL) 是美国最常见的淋巴瘤，每年影响约 22,000 人 对于以癌症患者为导向的研究来说，这是一个重要的临床问题，因为它是一种可治愈的疾病，但 具有异质性的结果。尽管超过 58% 的患者仍存活并在 5 年后通过现代化疗治愈 对于非裔美国人 (AA)、未投保或 具有激活的 B 细胞样 (ABC) 生物亚型或国际预后指数评分较高的患者。 Flowers 博士描述了 DLBCL 生物亚型的患者结果，确定了种族和种族 DLBCL 中的社会经济差异，并模拟种族/族裔、生物和社会经济因素如何影响 DLBCL 相互作用影响 DLBCL 的生存。但目前尚无统一、全面的预测方法 包含这些参数的系统。解决当前和长期未满足的健康需求 淋巴瘤患者群体，博士。 Flowers 和 Cerhan 建立了淋巴瘤流行病学结果 （LEO）队列研究（U01CA195568），该研究将支持旨在识别新颖的广泛研究议程 显着影响预后的临床、流行病学、宿主遗传、肿瘤和治疗因素 生存。 LEO 将： 1) 招募 >12,000 名新诊断淋巴瘤患者（包括 1,000 名 AA 和 1,400 名 西班牙裔参与者和 3,700 名 DLBCL）； 2）提取肿瘤DNA和RNA建立组织库， 外周血DNA、血清和血浆； 3) 对所有病例进行临床、流行病学、病理学和病理学注释 治疗数据； 4) 前瞻性随访患者以确定疾病进展/复发、再治疗、第二次治疗 癌症、生存率和患者报告的结果； 5）促进使用此的研究项目 基础设施。此外，Flowers 博士将利用 LEO 协议和佐治亚州 SEER 注册表来 构建一项基于人群的癌症差异队列研究，该研究将：1）检查之间的关系 DLBCL 基因组学、ABC 亚型、种族、表现模式、治疗和生存； 2）开发计算机 微观模拟模型将这些数据纳入 DLBCL 的在线预后工具中作为决策 为患者、临床医生和其他研究人员提供支持的工具。弗劳尔斯博士将在他的国家领导力的基础上继续发展 美国血液学促进多样性委员会、美国临床肿瘤学协会 健康差异委员会，以及 ASH 和淋巴瘤的临床研究指导计划 研究基金会并利用这些资源招募、培训和发展初级教师骨干， 血液学/肿瘤学研究员、家庭工作人员和医学生从事以癌症患者为导向的研究 特别注重培养将领导该领域的少数族裔调查员。